Vol. 19/No. 15

Kanti R. Rai, MD, has been a leader in the diagnosis and treatment of chronic lymphocytic leukemia for more than 40 years. He was honored in the Hematologic Malignancies category with a 2017 Giants of Cancer Care® award.

Rinath M. Jeselsohn, MD, discusses the detection and clinical implications of ESR1 mutations.

Bradley J. Monk, MD, and other gynecologic oncology experts from across the United States discussed how new evidence has affected their approach to treating advanced ovarian cancer.

Darcie Hurteau, MBA, and Alyssa Dahl, PhD, MPH, discuss the growing pains of the Oncology Care Model, a complicated payment program that is still establishing administrative processes.

Despite gaps in current knowledge, investigators are already working toward the development of novel treatment strategies to combat the effects of ESR1 mutations.

Investigators are evaluating the potential of LOXO-292, an oral small molecule inhibitor of RET signaling, to improve outcomes in patients with RET fusion–positive non–small cell lung cancer, medullary thyroid cancer, and other tumors.

Use of androgen deprivation therapy in combination with docetaxel or abiraterone in newly diagnosed cases of metastatic noncastrate prostate cancer is recommended in recently updated ASCO guidelines.

The Oncology Care Model is a patient-centric program that the Centers for Medicare & Medicaid Services says will allow for “better care, smarter spending, and healthier people.”

Tumor-treating field therapy, which uses low-intensity electrical fields to disrupt cancer cell division and promote cell death, has gained a frontline approval in glioblastoma. Several pivotal clinical trials have been launched to determine whether the technology can help patients with other solid tumors.

Maurie Markman, MD, discusses the increasing criticism of the phase III randomized trial in oncology.